NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial of radezolid in the treatment of community-acquired pneumonia (CAP).
In the double-blind study, radezolid was administered orally at three different doses: 300 mg once daily (QD), 450 mg QD and 450 mg twice daily (BID). This novel oxazolidinone showed comparable efficacy across all three doses, with clinical cure rates in the clinically evaluable population ranging from 78% to 92%. Radezolid also showed excellent activity against a number of key CAP pathogens including Streptococcus pneumoniae, methicillin-sensitive Staphylococcus aureus, Haemophilus influenzae and atypical respiratory pathogens. Additionally, radezolid was well tolerated, with the most commonly reported adverse events being mild gastrointestinal upset. No hematological adverse events were reported in this study.
"We are extremely encouraged by the positive results we've seen in this Phase 2 trial of radezolid in community-acquired pneumonia," said Susan Froshauer, PhD, President and CEO of Rib-X Pharmaceuticals. "Together with the previously reported positive results of the Phase 2 trial in uncomplicated skin infections, we are confident in the potential for radezolid to offer a safe therapeutic alternative for the treatment of methicillin-resistant Staphylococcus aureus and other bacterial infections. Radezolid has been shown to be efficacious and appears to have a favorable safety profile compared to other oxazolidinone compounds. We are looking forward to progressing the development of radezolid with the intravenous formulation in a more complicated disease setting."
|SOURCE Rib-X Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved